Table 6.
Comparison of Treatment with Glucocorticoids and Glucocorticoids Plus Antifungal Drugs
| Glucocorticoids (n=45) | Glucocorticoids Plus Antifungal Drugs (n=80) | P value | |
|---|---|---|---|
| Age (mean ± SD) | 51.73 ± 14.42 | 54.81 ± 14.54 | 0.56 |
| Male, n (%) | 26 (57.8%) | 42 (52.5%) | 0.43 |
| Mucus plugs, n (%) | 4 (8.89) | 7 (8.75) | 0.81 |
| Total eosinophil count cell (×10^9/L) (mean ± SD) | 1.49 ± 0.55 | 1.54 ± 0.88 | 0.84 |
| Total IgE level (IU/mL) (mean ± SD) | 4393.56 ± 1631.37 | 4447.42 ± 1456.34 | 0.51 |
| HRCT findings | |||
| Central Bronchiectasis, n (%) | 38 (84.4%) | 67 (83.8%) | 0.99 |
| Mucus plugs, n (%) | 17 (37.8%) | 27 (33.8%) | 0.75 |
| Spirometry (mean ± SD) | |||
| FVC% | 80.82 ± 10.81 | 78.34 ± 15.86 | 0.76 |
| FEV1% | 68.14 ± 15.87 | 67.13 ± 13.86 | 0.84 |
| FEV1/FVC | 70.11 ± 12.37 | 67.12 ± 14.58 | 0.43 |
| DLCO% | 83.44 ± 11.25 | 82.65 ± 14.57 | 0.75 |
| Clinical outcomes (mean ± SD) | |||
| The mean time to first ABPA exacerbation, month | 13.91 ± 3.13 | 15.64 ± 2.12 | 0.02 |
Abbreviations: IgE, immunoglobulin E; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide; SD, standard deviation.